First pig heart transplant patient dies after two months

First pig heart transplant patient dies after two months

WASHINGTON
First pig heart transplant patient dies after two months

The first person to receive a heart transplant from a genetically modified pig has died two months after the medical milestone, the hospital that carried out the surgery said on March 9.

The procedure raised hopes that advances in cross-species organ donation could one day solve the chronic shortage of human organs available for donation, and the team behind the operation say they still remain optimistic about its future success.

David Bennett, 57, had received his transplant on Jan. 7 and passed away March 8, the University of Maryland Medical System said in a statement.

“His condition began deteriorating several days ago. After it became clear that he would not recover, he was given compassionate palliative care. He was able to communicate with his family during his final hours,” the statement said.

Following surgery, the transplanted heart had performed very well for several weeks without any signs of rejection, the hospital added.

In the time after his surgery, Bennett spent time with family, participated in physical therapy, watched the Super Bowl and spoke often about wanting to go home to see his dog Lucky.

“He proved to be a brave and noble patient who fought all the way to the end. We extend our sincerest condolences to his family,” said Bartley Griffith, the surgeon who led the procedure.

Bennett came to the hospital in the eastern U.S. state of Maryland in October 2021. He was bedridden and placed on emergency life support machine. He had been deemed ineligible for human transplant, a decision that is often taken when the recipient has very poor underlying health.

“We have gained invaluable insights learning that the genetically modified pig heart can function well within the human body while the immune system is adequately suppressed,” said Muhammad Mohiuddin, director of the university’s cardiac xenotransplantation program.

“We remain optimistic and plan on continuing our work in future clinical trials.”